Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

142.39 +3.89 (+2.81%)
Official Closing Price Updated: 7:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,297,385
Open 138.01
Bid (Size) 142.26 (3)
Ask (Size) 143.00 (1)
Prev. Close 138.50
Today's Range 138.01 - 142.70
52wk Range 130.96 - 168.11
Shares Outstanding N/A
Dividend Yield 4.16%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Why Abbvie Stock Popped Today
The company announces a major deal worth over $10 billion. 
Via The Motley Fool

Performance

YTD
-12.31%
-12.31%
1 Month
+0.86%
+0.86%
3 Month
-3.11%
-3.11%
6 Month
+6.71%
+6.71%
1 Year
-11.66%
-11.66%

More News

Read More
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
Via InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
Via Investor's Business Daily
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
AbbVie Should Consider a Dividend Cut -- Here's Why
Via The Motley Fool
Medtronic Stock: Bull vs. Bear
Via The Motley Fool
How Is The Market Feeling About AbbVie?
Via Benzinga
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
Via InvestorPlace
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
Via Benzinga
These are the top sectors for blue chip growth in 2024
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
3 Rising Stars: Invest Now in Tomorrow’s Trillion-Dollar Companies
Via InvestorPlace
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Could AbbVie Stock Help You Become a Millionaire?
Via The Motley Fool
3 "Boring" Stocks That Could Make You Rich
Via The Motley Fool
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Via The Motley Fool
Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth
Via InvestorPlace
7 High-Yield Blue Chips Suitable for Any Retiree
Via InvestorPlace
Topics Retirement
Exposures Pension
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.